Teva Pharmaceutical Indus Q2 Adjusted EPS $0.56 Beats $0.54 Estimate, Sales $3.88B Beat $3.70B Estimate
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Indus (NYSE:TEVA) reported Q2 earnings of $0.56 per share, beating the analyst consensus estimate of $0.54 by 3.7%. However, this is a 17.65% decrease from the same period last year. The company also reported quarterly sales of $3.88 billion, beating the analyst consensus estimate of $3.70 billion by 4.81%, a 2.43% increase from the same period last year.
August 04, 2023 | 10:56 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Teva Pharmaceutical's Q2 earnings and sales beat estimates, but earnings are down from last year. This mixed result could lead to uncertain short-term price movement.
Teva beat earnings and sales estimates, which is generally positive for the stock price. However, the decrease in earnings compared to last year introduces uncertainty, which could limit the positive impact or even lead to a negative reaction in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100